ResearchAndMarkets.com added a global research on RNA therapies that profiles more than 80 companies and over 100 drug candidates. The research evaluates therapeutics by product type, development stage, administration route and molecule type and highlights inactive pipeline entries. It covers coding mRNA and non-coding RNAs, including siRNA, antisense oligonucleotides, aptamers, ribozymes and CRISPR/Cas approaches and categorizes RNA-based drugs into four classes: antisense oligonucleotides, siRNA, aptamers and mRNA.
Delivery challenges and approaches such as targeting moieties, lipid nanoparticles and direct organ delivery are examined alongside commercial assessments, collaborations and technology comparisons.
Company and product profiles cited include Novartis and Leqvio (inclisiran), Arrowhead Pharmaceuticals and ARO-APOC3, Arbutus Biopharm and AB-729, as well as ARO-C3, DCR-AUD, SGB-9768 and Cemdisiran.
The research also addresses emerging companies, pipeline stages, partnerships and novel technologies aimed at overcoming current therapeutic limitations.
